drugset / Trial / NCT00747318
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-05
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone propionate | Other / unclassified | 250 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 10 ug | Inhaled |